Skip to main content
. 2022 Sep 17;10(9):1549. doi: 10.3390/vaccines10091549

Figure 11.

Figure 11

(a) Timeframe to evaluate the formation of distant tumors (modeling and treatment), (b) and (c) volume change of primary and distant tumors, respectively; (d) mouse survival for the different treatments, (e) average tumor nodules in the lungs of immunized mice, (f) dissected lungs of immunized mice, and (g) H&E staining of lung sections for IDB-LDH and IDCB-LDH treated mice. * p < 0.05, ** p < 0.01, *** p < 0.001, n.s. = non-significant [95].